Pathophysiology and therapeutic needs in nonobstructive hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy (HCM) affects individuals worldwide with an estimated prevalence of over 1 in 500 individuals. Nonobstructive HCM accounts for approximately 30% to 70% of cases, is extremely heterogeneous, and is associated with a notable degree of morbidity, including daily life limitat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Desai, Milind (Verfasst von) , Maurizi, Niccolo (Verfasst von) , Biagini, Elena (Verfasst von) , Charron, Philippe (Verfasst von) , Fernandes, Fabio (Verfasst von) , González-López, Esther (Verfasst von) , van Haelst, Paul L. (Verfasst von) , Haugaa, Kristina Hermann (Verfasst von) , Kramer, Christopher M. (Verfasst von) , Meder, Benjamin (Verfasst von) , Michels, Michelle (Verfasst von) , Owens, Anjali (Verfasst von) , Yuasa, Shinsuke (Verfasst von) , Elliott, Perry (Verfasst von)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: November 2025
In: JACC Heart failure
Year: 2025, Jahrgang: 13, Heft: 11, Pages: 1-20
ISSN:2213-1787
DOI:10.1016/j.jchf.2025.102658
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.jchf.2025.102658
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2213177925005864
Volltext
Verfasserangaben:Milind Y. Desai, MD, MBA, Niccolo Maurizi, MD, Elena Biagini, MD, Philippe Charron, MD, PHD, Fabio Fernandes, MD, Esther González-López, MD, Paul L. van Haelst, MD, PHD, Kristina Hermann Haugaa, MD, Christopher M. Kramer, MD, Benjamin Meder, MD, Michelle Michels, MD, PHD, Anjali Owens, MD, Shinsuke Yuasa, MD, Perry Elliott, MBBS
Beschreibung
Zusammenfassung:Hypertrophic cardiomyopathy (HCM) affects individuals worldwide with an estimated prevalence of over 1 in 500 individuals. Nonobstructive HCM accounts for approximately 30% to 70% of cases, is extremely heterogeneous, and is associated with a notable degree of morbidity, including daily life limitations, ventricular tachyarrhythmias, progression to heart failure, and atrial fibrillation. No approved pharmaceutical therapies target the pathophysiology of nonobstructive HCM, although several clinical trials are underway. This narrative review provides a comprehensive overview of nonobstructive HCM, focusing on epidemiology, natural history, genetics, pathophysiology, clinical manifestations, diagnosis, burden of disease, and current treatments and ongoing clinical trials.
Beschreibung:Online veröffentlicht am 24. September 2025
Gesehen am 17.04.2026
Beschreibung:Online Resource
ISSN:2213-1787
DOI:10.1016/j.jchf.2025.102658